Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT06605599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar I Disorder
Bipolar II Disorder

Interventions

DRUG: ABBV-932
DRUG: Placebo for ABBV-932

Sponsor

AbbVie